Articles Posted in Elmiron

Our lawyers handle Elmiron vision loss lawsuits throughout the country.

This page provides the latest news and updates on the Elmiron class action lawsuit and provides our prediction of the settlement amounts, vision loss, and blindness victims who bring an Elmiron lawsuit will ultimately receive.

Elmiron settlements are happening in 2024.  Many victims have agreed to settlement amounts and will receive settlement checks shortly if they have not already.  Many Elmiron lawyers have stopped taking new Elmiron clients, including us.  We keep this information up to keep you updated because we are still committed to victims.  We have February 2024 updates below.

In 2019 it was discovered that prolonged use of the prescription drug Elmiron can cause a unique type of macular eye damage (pigmentary maculopathy), resulting in vision loss or impairment. This condition involves changes to the macula, the central part of the retina that is responsible for sharp, detailed vision. This led to a growing wave of Elmiron lawsuits by people who suffered vision loss from taking this drug.

The Elmiron lawsuits were consolidated into a class action MDL in federal court in New Jersey. In this post, we will look at how the Elmiron litigation has developed, the most recent events, and discuss what to expect in 2023 in this ongoing mass tort. \

Janssen is settling the pending Elmiron cases in large blocks.

Elmiron is a prescription drug used by millions for the treatment of bladder conditions. In 2019, new research revealed that long-term use of Elmiron can cause permanent vision loss. This prompted thousands of Elmiron lawsuits which were consolidated into a class action MDL.

It has now been almost 2 years since the Elmiron class action lawsuit was formed. In this post, we will look at what has been going on in the Elmiron class action recently and speculate on when we could potentially see a global settlement.

About the Elmiron Lawsuits

Our lawyers are handling Elmiron macular eye injury lawsuits in all 50 states alleging that victims’ macular degeneration was caused by the use of the drug for interstitial cystitis.

Elmiron is the brand name for pentosan polysulfate sodium, a prescription drug that is used by millions to treat a bladder condition called interstitial cystitis (IC).

In 2018, however, medical researchers discovered that prolonged use of Elmiron can cause some users to develop a new eye disease called pigmentary maculopathy which can result in vision impairment and blindness. Pigmentary maculopathy is only known to be caused by long-term use of pentosan polysulfate sodium.

Elmiron vision loss lawsuits are being filed at an increasing rate. Anyone that has been using the drug Elmiron to treat bladder conditions should be aware of the growing tide of concerns regarding the long-term side effects of this popular drug for interstitial cystitis.

After an initial wave of reports linking the use of Elmiron to serious vision impairment, the Food and Drug Administration (FDA) has recently stepped in and required the manufacturer of Elmiron to add a  new warning label.

The new warning label alerts doctors and patients that Elmiron may cause a rare eye disease called pigmentary maculopathy that can cause vision impairment or blindness. The new warning label comes just as Elmiron vision loss lawsuits are already being filed across the country. Ultimately, when an Elmiron class action settlement is reached down the road, I predict a strong, unambiguous black box warning of the side effects that include vision loss.

Contact Information